Stanislaw Malicki

Stanislaw Malicki

Auto-generated profile, based on publicly available information

Stanislaw Malicki

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnologies, Jagiellonian University, Krakow, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
MKMagdalena Kaczor
Magdalena Kaczor
SMStanislaw Malicki
Stanislaw Malicki
JFJustyna Folkert
Justyna Folkert
EDEwelina Dobosz
Ewelina Dobosz
DBDanuta Bryzek
Danuta Bryzek
FVFlorian Veillard
Florian Veillard
Neutropenia and neutrophil dysfunction in glycogen storage disease type 1b (GSD1b) are caused by the accumulation of 1,5-anhydroglucitol-6-phosphate in granulocytes. The antidiabetic drug empagliflozin reduces the concentration of 1,5-anhydroglucitol (1,5-AG), thus restoring neutrophil counts and functions, leading to promising results in previous case reports. Here, we present a comprehensive analysis of neutrophil function in 7 patients with GSD1b and 11 healthy donors, aiming to evaluate the immediate (after 3 months) and long-term (after 12 months) efficacy of empagliflozin compared with the reference treatment with granulocyte-colony stimulating factor (G-CSF). We found that most patients receiving G-CSF remained neutropenic with dysfunctional granulocytes, whereas treatment with empagliflozin increased neutrophil counts and improved functionality by inhibiting apoptosis, restoring phagocytosis and the chemotactic response, normalizing the oxidative burst, and stabilizing cellular and plasma levels of defensins and lactotransferrin. These improvements correlated with the decrease in serum 1,5-AG levels. However, neither G-CSF nor empagliflozin overcame deficiencies in the production of cathelicidin/LL-37 and neutrophil extracellular traps. Given the general improvement promoted by empagliflozin treatment, patients were less susceptible to severe infections. G-CSF injections were therefore discontinued in 6 patients (and the dose was reduced in the seventh) without adverse effects. Our systematic analysis, the most extensive reported thus far, has demonstrated the superior efficacy of empagliflozin compared with G-CSF, restoring the neutrophil population and normal immune functions. This trial was registered as EudraCT 2021-000580-78.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
TCT.J. Chen
T.J. Chen
PMPiotr Mateusz Mydel
Piotr Mateusz Mydel
MBM. Benedyk-Machaczka
M. Benedyk-Machaczka
SMS. Malicki
S. Malicki
JFJessica Furriol
Jessica Furriol
HMH-P. Marti
H-P. Marti